LSL Pharma Group Inc.
LSL.V
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.94M | 3.06M | 3.09M | 2.54M | 1.87M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.94M | 3.06M | 3.09M | 2.54M | 1.87M |
| Cost of Revenue | 2.06M | 1.94M | 2.24M | 2.47M | 1.52M |
| Gross Profit | 875.40K | 1.12M | 850.00K | 73.10K | 347.40K |
| SG&A Expenses | 786.70K | 1.22M | 717.20K | 38.70K | 510.70K |
| Depreciation & Amortization | 25.70K | -- | -- | -- | 24.60K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.88M | 3.17M | 2.96M | 2.45M | 2.06M |
| Operating Income | 63.10K | -103.80K | 132.80K | 90.30K | -187.90K |
| Income Before Tax | -283.00K | -377.10K | -207.70K | -349.80K | -568.10K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -283.00K | -377.10K | -207.70K | -349.80K | -568.10K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -283.00K | -377.10K | -207.70K | -349.80K | -568.10K |
| EBIT | 63.10K | -103.80K | 132.80K | 90.30K | -187.90K |
| EBITDA | 322.60K | 149.10K | 380.50K | 104.50K | 70.80K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 115.08M | 105.77M | 84.58M | 82.56M | 82.43M |
| Average Diluted Shares Outstanding | 115.28M | 105.89M | 84.58M | 82.56M | 82.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
